Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 24 March 2020 Roche response to COVID-19 pandemic more Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more Published on: 17 March 2020 Roche Annual General Meeting 2020 more Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more Published on: 30 January 2020 Roche reports very strong results in 2019 more Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more
Published on: 23 March 2020 Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia more
Published on: 19 March 2020 Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia more
Published on: 16 March 2020 Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance more
Published on: 14 March 2020 Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended more
Published on: 13 March 2020 Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark more
Published on: 12 March 2020 European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia more
Published on: 11 March 2020 Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention more
Published on: 4 March 2020 FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma more
Published on: 25 February 2020 FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer more
Published on: 19 February 2020 FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer more
Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more
Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more
Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more
Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more
Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more
Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more
Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more
Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more